Yıl: 2022 Cilt: 26 Sayı: 3 Sayfa Aralığı: 109 - 114 Metin Dili: İngilizce DOI: 10.5152/tjem.2022.22022 İndeks Tarihi: 25-09-2022

Sporadic Adrenocorticotropic Hormone-Secreting Lung Carcinoids: Outcomes of Long-Term Clinical Follow-Up at a Single Center

Öz:
Objective: Lung carcinoids represent a small portion of all lung tumors and about 1%-5% are associ ated with ectopic adrenocorticotropic hormone secretion, representing 1%-10% of Cushing’s syn drome. They occur both sporadically and rarely in association with multiple endocrine neoplasia type 1. MEN1 variations were detected in approximately 16% of sporadic cases with seldom reports about disease prognosis. This study aimed to identify MEN1 variants in our cohort of sporadic lung carci noids to associate with disease outcome following surgery. Methods: Pathologically confirmed 5 lung carcinoid cases were retrospectively analyzed in terms of age, gender, imaging studies, clinicopathologic features, and long-term disease outcome. Genetic analysis was performed to detect copy number variations and point mutations in MEN1. Results: Totally 1 female and 4 males with cushingoid features underwent thoracoscopic lobectomy for ectopic Cushing’s syndrome. Histopathological examinations revealed 2 atypical (males) and 3 typ ical (1 female and 2 males) carcinoids. One underwent Wedge resection, the others underwent lobec tomy; none of them had any post-operative complications. Median follow-up period was 11 years (range, 5-19); all patients were alive with no recurrence or metastases, up to date. Genetic analysis revealed a novel MEN1 variant [c.1623G>T, p.(Gln541His)] in only 1 atypical carcinoid. Despite this variant, this case did not develop other components of MEN1 syndrome during long-term follow-up. Conclusion: We detected the frequency of MEN1 variation as 20%. Further studies are required to clarify the role of this variant.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Thakker RV, Newey PJ, Walls GV, et al. Clinical practice guidelines for mul tiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab. 2012;97(9):2990-3011. [CrossRef]
  • 2. Kouvaraki MA, Lee JE, Shapiro SE, et al. Genotype-phenotype analysis in multiple endocrine neoplasia type 1. Arch Surg. 2002;137(6):641-647. [CrossRef]
  • 3. Lemos MC, Thakker RV. Multiple endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations reported in the first decade following iden tification of the gene. Hum Mutat. 2008;29(1):22-32. [CrossRef]
  • 4. Pieterman CR, Schreinemakers JM, Koppeschaar HP, et al. Multiple endo crine neoplasia type 1 (MEN1): its manifestations and effect of genetic screening on clinical outcome. Clin Endocrinol (Oxf). 2009;70(4):575-581. [CrossRef]
  • 5. Ullmann U, Unuane D, Velkeniers B, Lissens W, Wuyts W, Bonduelle M. A new double substitution mutation in the MEN1 gene: a limited pene trance and a specific phenotype. Eur J Hum Genet. 2013;21(6):695-697. [CrossRef]
  • 6. Yao JC, Hassan M, Phan A, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063-3072. [CrossRef]
  • 7. Travis WD, Brambilla E, Nicholson AG, et al. The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 2015;10(9):1243-1260. [CrossRef]
  • 8. Wolin EM. Advances in the diagnosis and management of well-differen tiated and intermediate-differentiated neuroendocrine tumors of the lung. Chest. 2017;151(5):1141-1146. [CrossRef]
  • 9. Piro R, Tonelli R, Taddei S, et al. Atypical diagnosis for typical lung carci noid. BMC Pulm Med. 2019;19(1):168. [CrossRef]
  • 10. Kenchaiah M, Hyer S. Cushing's syndrome due to ectopic ACTH from bronchial carcinoid: A case report and review. Case Rep Endocrinol. 2012;2012:215038. [CrossRef]
  • 11. Isidori AM, Kaltsas GA, Pozza C, et al. The ectopic adrenocorticotropin syndrome: clinical features, diagnosis, management, and long-term fol low-up. J Clin Endocrinol Metab. 2006;91(2):371-377. [CrossRef]
  • 12. Nieman LK, Biller BM, Findling JW, et al. The diagnosis of Cushing's syn drome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2008;93(5):1526-1540. [CrossRef]
  • 13. Brokx HA, Paul MA, Postmus PE, Sutedja TG. Long-term follow-up after first-line bronchoscopic therapy in patients with bronchial carcinoids. Thorax. 2015;70(5):468-472. [CrossRef]
  • 14. Kaifi JT, Schmid S, Passlick B. Typical and atypical carcinoids of the lung: a surgical treatment strategy. Zentralbl Chir. 2016;141(1):105-120. [CrossRef]
  • 15. Mashaal H, Sexton R, Anjum F. Bronchial Carcinoid Tumors. StatPearls Publishing. Treasure Island, FL; 2022.
  • 16. Degnan AJ, Tadros SS, Tocchio S. Pediatric neuroendocrine carcinoid tumors: review of diagnostic imaging findings and recent advances. AJR Am J Roentgenol. 2017;208(4):868-877. [CrossRef]
  • 17. Costa SC, Nascimento LS, Ferreira FJ, Mattos PS, Camara-Lopes LH, Ward LS. Lack of mutations of exon 2 of the MEN1 gene in endocrine and nonendocrine sporadic tumors. Braz J Med Biol Res. 2001;34(7):861- 865. [CrossRef]
  • 18. Swarts DR, Ramaekers FC, Speel EJ. Molecular and cellular biology of neuroendocrine lung tumors: evidence for separate biological entities. Biochim Biophys Acta. 2012;1826(2):255-271. [CrossRef]
  • 19. Righi L, Volante M, Rapa I, Scagliotti GV, Papotti M. Neuro-endocrine tumours of the lung. A review of relevant pathological and molecular data. Virchows Arch. 2007;451(suppl 1):S51-S59. [CrossRef]
  • 20. Debelenko LV, Brambilla E, Agarwal SK, et al. Identification of MEN1 gene mutations in sporadic carcinoid tumors of the lung. Hum Mol Genet. 1997;6(13):2285-2290. [CrossRef]
  • 21. Görtz B, Roth J, Krähenmann A, et al. Mutations and allelic deletions of the MEN1 gene are associated with a subset of sporadic endocrine pan creatic and neuroendocrine tumors and not restricted to foregut neo plasms. Am J Pathol. 1999;154(2):429-436. [CrossRef]
  • 22. Finkelstein SD, Hasegawa T, Colby T, Yousem SA. 11q13 allelic imbalance discriminates pulmonary carcinoids from tumorlets. A microdissection based genotyping approach useful in clinical practice. Am J Pathol. 1999;155(2):633-640. [CrossRef]
  • 23. Simbolo M, Mafficini A, Sikora KO, et al. Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for tert, RB1, MEN1 and KMT2D. J Pathol. 2017;241(4):488-500. [CrossRef]
  • 24. Concolino P, Costella A, Capoluongo E. Multiple endocrine neoplasia type 1 (MEN1): an update of 208 new germline variants reported in the last nine years. Cancer Genet. 2016;209(1-2):36-41. [CrossRef]
  • 25. Modlin IM, Sandor A. An analysis of 8305 cases of carcinoid tumors. Can cer. 1997;79(4):813-829. [CrossRef]
  • 26. Swarts DR, Scarpa A, Corbo V, et al. MEN1 gene mutation and reduced expression are associated with poor prognosis in pulmonary carcinoids. J Clin Endocrinol Metab. 2014;99(2):E374-E378. [CrossRef]
  • 27. Dermawan JK, Farver CF. The Prognostic Significance of the 8th Edition TNM Staging of Pulmonary Carcinoid Tumors: A Single Institution Study With Long-term Follow-up. Am J Surg Pathol. 2019;43(9):1291-1296. [CrossRef]
  • 28. Caplin ME, Baudin E, Ferolla P, et al. Pulmonary neuroendocrine (carci noid) tumors: European Neuroendocrine Tumor Society expert consen sus and recommendations for best practice for typical and atypical pul monary carcinoids. Ann Oncol. 2015;26(8):1604-1620. [CrossRef]
APA yarman s, SERBEST E, Soyluk Selcukbiricik O, Tuncer F (2022). Sporadic Adrenocorticotropic Hormone-Secreting Lung Carcinoids: Outcomes of Long-Term Clinical Follow-Up at a Single Center. , 109 - 114. 10.5152/tjem.2022.22022
Chicago yarman sema,SERBEST ESİN,Soyluk Selcukbiricik Ozlem,Tuncer Feyza Sporadic Adrenocorticotropic Hormone-Secreting Lung Carcinoids: Outcomes of Long-Term Clinical Follow-Up at a Single Center. (2022): 109 - 114. 10.5152/tjem.2022.22022
MLA yarman sema,SERBEST ESİN,Soyluk Selcukbiricik Ozlem,Tuncer Feyza Sporadic Adrenocorticotropic Hormone-Secreting Lung Carcinoids: Outcomes of Long-Term Clinical Follow-Up at a Single Center. , 2022, ss.109 - 114. 10.5152/tjem.2022.22022
AMA yarman s,SERBEST E,Soyluk Selcukbiricik O,Tuncer F Sporadic Adrenocorticotropic Hormone-Secreting Lung Carcinoids: Outcomes of Long-Term Clinical Follow-Up at a Single Center. . 2022; 109 - 114. 10.5152/tjem.2022.22022
Vancouver yarman s,SERBEST E,Soyluk Selcukbiricik O,Tuncer F Sporadic Adrenocorticotropic Hormone-Secreting Lung Carcinoids: Outcomes of Long-Term Clinical Follow-Up at a Single Center. . 2022; 109 - 114. 10.5152/tjem.2022.22022
IEEE yarman s,SERBEST E,Soyluk Selcukbiricik O,Tuncer F "Sporadic Adrenocorticotropic Hormone-Secreting Lung Carcinoids: Outcomes of Long-Term Clinical Follow-Up at a Single Center." , ss.109 - 114, 2022. 10.5152/tjem.2022.22022
ISNAD yarman, sema vd. "Sporadic Adrenocorticotropic Hormone-Secreting Lung Carcinoids: Outcomes of Long-Term Clinical Follow-Up at a Single Center". (2022), 109-114. https://doi.org/10.5152/tjem.2022.22022
APA yarman s, SERBEST E, Soyluk Selcukbiricik O, Tuncer F (2022). Sporadic Adrenocorticotropic Hormone-Secreting Lung Carcinoids: Outcomes of Long-Term Clinical Follow-Up at a Single Center. Turkish Journal of Endocrinology and Metabolism, 26(3), 109 - 114. 10.5152/tjem.2022.22022
Chicago yarman sema,SERBEST ESİN,Soyluk Selcukbiricik Ozlem,Tuncer Feyza Sporadic Adrenocorticotropic Hormone-Secreting Lung Carcinoids: Outcomes of Long-Term Clinical Follow-Up at a Single Center. Turkish Journal of Endocrinology and Metabolism 26, no.3 (2022): 109 - 114. 10.5152/tjem.2022.22022
MLA yarman sema,SERBEST ESİN,Soyluk Selcukbiricik Ozlem,Tuncer Feyza Sporadic Adrenocorticotropic Hormone-Secreting Lung Carcinoids: Outcomes of Long-Term Clinical Follow-Up at a Single Center. Turkish Journal of Endocrinology and Metabolism, vol.26, no.3, 2022, ss.109 - 114. 10.5152/tjem.2022.22022
AMA yarman s,SERBEST E,Soyluk Selcukbiricik O,Tuncer F Sporadic Adrenocorticotropic Hormone-Secreting Lung Carcinoids: Outcomes of Long-Term Clinical Follow-Up at a Single Center. Turkish Journal of Endocrinology and Metabolism. 2022; 26(3): 109 - 114. 10.5152/tjem.2022.22022
Vancouver yarman s,SERBEST E,Soyluk Selcukbiricik O,Tuncer F Sporadic Adrenocorticotropic Hormone-Secreting Lung Carcinoids: Outcomes of Long-Term Clinical Follow-Up at a Single Center. Turkish Journal of Endocrinology and Metabolism. 2022; 26(3): 109 - 114. 10.5152/tjem.2022.22022
IEEE yarman s,SERBEST E,Soyluk Selcukbiricik O,Tuncer F "Sporadic Adrenocorticotropic Hormone-Secreting Lung Carcinoids: Outcomes of Long-Term Clinical Follow-Up at a Single Center." Turkish Journal of Endocrinology and Metabolism, 26, ss.109 - 114, 2022. 10.5152/tjem.2022.22022
ISNAD yarman, sema vd. "Sporadic Adrenocorticotropic Hormone-Secreting Lung Carcinoids: Outcomes of Long-Term Clinical Follow-Up at a Single Center". Turkish Journal of Endocrinology and Metabolism 26/3 (2022), 109-114. https://doi.org/10.5152/tjem.2022.22022